Please login to the form below

Not currently logged in
Email:
Password:

Opdivo drives growth at BMS, but US sales slow down

Sales beginning to lose momentum despite new indications bringing in $1.3bn for Q4

Bristol-Myers SquibbBristol-Myers Squibb's immuno-oncology blockbuster Opdivo continued its phenomenal growth in the last three months of 2016, but is showing signs of losing momentum.

Opdivo sales more than doubled to $1.3bn in the quarter, up from $475m a year ago, but is expected to experience some slowdown after the drug failed a trial in first-line non-small cell lung cancer (NSCLC), handing an advantage to Merck & Co's rival therapy Keytruda (pembrolizumab).

Quarter-on-quarter growth gives an indication that may already be happening. BMS recorded sales of $920m for Opdivo in the third-quarter last year so the overall trend remains strong. In the US however, third quarter sales came in a $712m in Q3 and barely moved to $715m in the last three months of the year.

BMS has now cut its guidance for 2017 by 15 cents, saying it expects earnings per share to be in the $2.70-$2.90 range, which analysts have attributed at least in part to the Opdivo effect and the prospect of competition from new immuno-oncology drugs from the likes of Roche, Pfizer/Merck KGaA and AstraZeneca.

One analyst - Leerink's Seamus Fernandez - suggested the near-term weakness could even make BMS a takeover target, particularly as Opdivo is still firmly tipped for mega-blockbuster status as new indications are added to its label.

BMS has just picked up FDA approval for Opdivo for second-line squamous cell carcinoma of the head and neck (SCCHN), and a European approval in relapsed or refractory classical Hodgkin lymphoma, adding to existing approvals in melanoma, second-line NSCLC and renal cell carcinoma.

Overall, BMS reported fourth-quarter revenues up 22% to $5.2bn, with a solid showing from novel oral anticoagulant Eliquis (apixaban), which leaped 57% to $346m and rheumatoid arthritis therapy Orencia (abatacept), which was up 16% to $625m.

Fourth-quarter sales for BMS' other immuno-oncology drug Yervoy (ipilimumab) were however largely flat compared to the prior-year period at $264m. The company has just abandoned plans to seek accelerated approval for Opdivo plus Yervoy in first-line NSCLC, setting back a possible approval to the latter half of 2018.

Article by
Phil Taylor

27th January 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

women
Advancing women in healthcare
Fostering the next generation of leaders...
The Challenges Of UX In Healthcare: Technology To Change Lives
Blue Latitude Health Director and Head of Customer Experience Elisa Del Galdo explores the latest digital healthcare trends and reveals the innovations changing the sector today....
It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...

Infographics